Prescribing overview
Itrafungol is a feline oral solution for Microsporum canis ringworm. It is not sporicidal; topical/environmental management remains necessary to reduce contamination and zoonotic risk.
Key prescribing checks
- Review liver function and clinically important drug interactions. Itraconazole can affect metabolism of other medications, and human capsule labeling includes cardiac warnings.
- The feline label requires benefit-risk assessment in pregnant or lactating cats and avoidance in itraconazole hypersensitivity.
- Ringworm management also needs topical/environmental measures and exposure precautions. Oral improvement alone does not establish that spores or zoonotic risk are eliminated.
- Document appetite loss, vomiting, diarrhea and suspected intolerance within the veterinarian’s follow-up plan.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Cats
FDA-approved Itrafungol indicationM. canis dermatophytosis
This regimen is not for human Sporanox capsules or other fungal indications.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Inhibits fungal cytochrome P450-dependent ergosterol synthesis, disrupting membranes.
Absorption, distribution, metabolism and elimination
Laboratory cats: food delayed median peak from 2 to 4 hours, reduced peak concentration, and slightly increased total exposure.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Itrafungol
U.S. feline oral-solution label.
Contraindications · when not to use
- Itraconazole hypersensitivity.
Precautions & monitoring
- Pregnancy/lactation requires benefit-risk assessment; monitor gastrointestinal intolerance and liver concerns.
Sporanox
U.S. human oral-capsule label; not veterinary approval or interchangeable with solution.
Contraindications · when not to use
- Itraconazole hypersensitivity.
- For human nail infection: ventricular dysfunction/CHF history, pregnancy or planned pregnancy.
- Numerous prohibited drug combinations; see full label, including conditional renal/hepatic/metabolizer restrictions.
Precautions & monitoring
- Cardiac dysfunction for other indications requires compelling benefit-risk assessment; liver toxicity is a warning.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Vomiting, diarrhea, appetite loss, liver-enzyme increases and jaundice are reported.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| CatsM. canis dermatophytosisItrafungol 10 mg/mL oral solution | 5 mg/kg (0.5 mL/kg) Oral · Once daily during treatment weeks Weeks 1, 3 and 5 treated; weeks 2 and 4 untreated (3 cycles) | Use enclosed graduated syringe; with/without food. Verify full dosing label ↗ |
Pregnancy/lactation requires benefit–risk assessment; avoid hypersensitivity.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Sporanox
U.S. human oral-capsule label; not veterinary approval or interchangeable with solution.
- Contraindicated examples include cisapride, quinidine, methadone, oral midazolam and triazolam; this list is incomplete.
Monitoring
Review appetite, weight, gastrointestinal tolerance and liver concerns.
Client counseling
Wear gloves handling infected cats; wash exposed skin; clean and dry syringe.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
20–25°C; permitted excursions 15–30°C; close cap tightly.
Brands, formulations & ingredient identity
Active ingredients
itraconazole
Itrafungol is an oral solution, not an injectable product, even though a DailyMed metadata heading incorrectly says injection. The prescribing text explicitly establishes the oral route.
Sporanox capsules and oral solution have different absorption characteristics. Capsules, veterinary solution and compounded preparations are not automatically interchangeable.
Record the exact brand, route and formulation. Human systemic-fungal indications must not be assumed to be Itrafungol’s feline label indications.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Itrafungol
- Formulation
- 10 mg/mL oral solution
- Label / product scope
- Cats
Feline dermatophytosis product; oral route verified in prescribing text.
Product label / source ↗Sporanox
- Formulation
- Oral capsules
- Label / product scope
- Human product
Human itraconazole brand; formulation-specific absorption and warnings apply.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →